The Relationship Between the Differential Expression of FosB Protein in Laryngeal Cancer Tissues and Clinical Prognosis
NCT ID: NCT06836765
Last Updated: 2025-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-04-01
2025-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
NCT06850506
Oncologic and Functional Outcome and Quality of Life in Patients Treated for Laryngeal Cancer
NCT06784401
Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma
NCT01171235
Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma
NCT06770699
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
NCT07186855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
secondly,if there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. Review the clinical data of corresponding patients, including age, gender, smoking and alcohol history, clinical stages, pathological types and clinical prognosis, etc., and compare whether there are statistical differences.
Finally, clinical prognostic data of relevant patients were collected through outpatient follow-up, online and telephone follow-up, to determine whether there is a correlation between Fosb expression in laryngeal cancer tissue and clinical prognosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The expression of FosB positive group
Researcher will incorporate the positive expression of FosB protein in laryngeal cancer tissues into the positive study group by immunohistochemical methods!
the expression positive in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
The expression of FosB negative group
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
the expression negative in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the expression negative in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
the expression positive in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary tumor of Laryngeal ,and there was no distant metastasis;
* Standard treatment such as surgery and Preliminarily-diagnosed parients;
* full clinical and pathological data information and good follow-up;
* there was no previous fatal diseases such as complicated tumors.
Exclusion Criteria
* Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;
* Clinical and pathological data were missing and loss to follow-up;
* Patients who abandoned treatment or standard treatment procedures has not been completed;
* The past medical history of other lethal diseases such as complicated tumors.
35 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yang ji
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yang ji
associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cllinical Laboratory of Chuanbei Medical College
Nanchong, China/SiChuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003 Nov;3(11):859-68. doi: 10.1038/nrc1209. No abstract available.
Liu S, Luan J, Ding Y. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. Oncol Res. 2018 Jun 11;26(5):683-690. doi: 10.3727/096504017X14982585511252. Epub 2017 Jun 24.
Hung YP, Fletcher CD, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017 May;41(5):596-606. doi: 10.1097/PAS.0000000000000795.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NeijiangPH2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.